Living with chronic pain?
It’s time to explore a new option.
See if the MOSAIC Study is right for you.
Chronic pain affects 1 in 5 adults, and can impact nearly every aspect of daily life – from work performance, to family life, to social interactions.1 For many people, this pain affects the lower back and/or legs, and can be caused by a variety of underlying conditions.
If you’ve struggled with chronic low back and/or leg pain for at least 6 months that has not responded to other treatments, you may be a candidate for the MOSAIC Study. The study uses the WaveWriter™ Spinal Cord Stimulator System – an FDA-approved, drug-free therapy shown to effectively relieve pain and improve quality of life.2,3
What is WaveWriter™ SCS?
The WaveWriter Spinal Cord Stimulator (SCS) System is an FDA-approved therapy for people with chronic pain. Spinal cord stimulation is a safe, drug-free solution for treating chronic pain that uses a small implanted device called a neurostimulator. The neurostimulator sends mild pulses of energy to the spinal cord to mask or modify pain signals before you feel them. SCS systems also come with a mobile, handheld remote control that lets you adjust the stimulation to your needs.
A key benefit of SCS is that you can try it for a period of time (usually 3 – 7 days) to decide whether it’s right for you. To try out SCS, you’ll simply be fitted with a temporary device that works like an implanted system, but you will use a small external generator (that can easily hide under your clothing). If after the trial period you are satisfied with your pain relief, you can choose to have the system implanted. This is done through a short, reversible surgical procedure to place the neurostimulator beneath the skin.
The WaveWriter SCS System provides parasthesia-free therapy. Many SCS systems replace your pain with a tingling sensation, called “parasthesia.” The WaveWriter SCS uses a type of stimulation you don’t feel at all.
Learn how SCS therapy works
Hear about Karen’s experience with SCS therapy
The MOSAIC Study
Doctors at select US centers are conducting the MOSAIC Study. The purpose is to evaluate a new kind of stimulation with WaveWriter called Time Variant Pulse (TVP). Instead of sending the same type of electrical signal all the time, this method changes how the signal is delivered like adjusting the strength, speed, and length of the pulses.
If you qualify and choose to join the MOSAIC Study, you will be treated by a local physician specialist and will be compensated for your time and effort to attend routine follow-up visits over a 2-year period, up to a total of $6,600.
Why Participate?
If you’ve struggled with chronic low back and/or leg pain for at least 6 months that has not responded to other treatments, you may be a candidate for the MOSAIC Study. The study uses the WaveWriter Spinal Cord Stimulator System – an FDA-approved drug-free therapy shown to effectively relieve pain and improve quality of life. If you qualify and choose to join the MOSAIC study you will receive:
- Evaluations of your pain by a local physician specialist
- Treatment with the WaveWriter SCS System
- Compensation for your time and effort to attend routine follow-up visits over a 2-year period, up to a total of $6,600.
- The opportunity to help advance new treatments for chronic pain, which may benefit oothers who struggle with similar symptoms
See If You Qualify
To see if you might qualify for the MOSAIC Study, and to get connected with your local study center to learn more, please take the questionnaire below:
References:
- Dahlhamer J, Lucas J, Zelaya, C, et al. Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States, 2016. MMWR Morb Mortal Wkly Rep 2018;67:1001–1006.
- Veizi E, Hayek SM, North J, et al. Spinal cord stimulation (SCS) with anatomically guided (3D) neural targeting shows superior chronic axial low back pain relief compared to traditional SCS—LUMINA Study. Pain Med. 2017;18(8):1534-1548.
- Thomson SJ, Kruglov D, Duarte RV. A spinal cord stimulation service review from a single centre using a single manufacturer over a 7.5 year follow-up period. Neuromodulation. 2017;20(6):589-599. N=321